Form 4: AN2 Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Robin Shane Readnour, a Director of AN2 Therapeutics, Inc., sold 1,108 shares of common stock on September 9, 2026 for $6.02 per share.
Summary
- Open-market sale: disposed of 523 Common Stock at $6.02 ($3,151) on September 9, 2026; holds 557,467 after (Indirect).
- Open-market sale: disposed of 585 Common Stock at $6.02 ($3,524) on September 9, 2026; holds 624,765 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,675 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Robin Shane Readnour — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Open-market sale | Common Stock | 523 | $6 | $3.2K | 557,467 |
| 2026-09-09 | Open-market sale | Common Stock | 585 | $6 | $3.5K | 624,765 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Open-market sale (523 shares) |
| 2026-09-09 | Open-market sale (585 shares) |
Keywords
insider transaction, Form 4, ANTX, AN2 Therapeutics, Inc., bearish, Robin Shane Readnour
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.